nuclear pore complex interacting protein family member B2Genealiases: []
Q-omics provides the consensus-scored NPIPB2 profile across patient tissues and cancer cell-line models. NPIPB2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, NPIPB2 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, NPIPB2 RNA expression shows 7,058 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, BRCA, and UVM as cancer lineages where NPIPB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPIPB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPIPB2 survival associations across molecular data types. NPIPB2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPIPB2 RNA expression–survival associations across cancer types. High NPIPB2 expression shows unfavorable associations in OV, KIRP and MESO, but favorable associations in LAML, UCEC and LGG. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for NPIPB2 RNA expression.
This table summarizes NPIPB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NPIPB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPIPB2 shows lower tumor expression in BRCA and READ and higher tumor expression in CHOL and LIHC. The BRCA box plot shows higher NPIPB2 RNA expression in normal versus tumor tissue (log2 FC = −0.235, t-test p = .016).
This table shows molecular features associated with NPIPB2 in patient tissues and cancer cell lines. In patient samples, NPIPB2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
